Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate

MT Newswires Live05-19

Alterity Therapeutics (ASX:ATH) said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.

One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.

Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.

"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy," said Alterity Therapeutics CEO David Stamler.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636881349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 11:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636881349","market":"hk","top_or_hot":-1,"title":"Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> (ASX:ATH) said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.</p><p>One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.</p><p>Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.</p><p>\"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy,\" said Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO David Stamler.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 11:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> (ASX:ATH) said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.</p><p>One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.</p><p>Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.</p><p>\"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy,\" said Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> CEO David Stamler.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATH.AU","symbol_name":"ALTERITY THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636881349","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636881349","pubTimestamp":1779162331,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alterity Therapeutics  said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.\"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy,\" said Alterity Therapeutics CEO David Stamler.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATH.AU":"ALTERITY THERAPEUTICS LTD","BK4139":"生物科技","BK7067":"生物科技","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股"},"translate_title":"Alterity Therapeutics表示数据演示支持多系统萎缩治疗候选药物的第三阶段开发","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATH.AU":1,"LENZ":1.5},"content_text":"Alterity Therapeutics (ASX:ATH) said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.\"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy,\" said Alterity Therapeutics CEO David Stamler.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636881349","isCrawlerRequest":true}